Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

SP. Robinson, A. Boumendil, H. Finel, D. Blaise, X. Poiré, E. Nicolas-Virelizier, R. Or, R. Malladi, A. Corby, L. Fornecker, D. Caballero, D. Pohlreich, A. Nagler, C. Thieblemont, J. Finke, E. Bachy, L. Vincent, W. Schroyens, H. Schouten, P. Dreger,

. 2016 ; 51 (3) : 365-71. [pub] 20151130

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000834

E-zdroje NLK Online Plný text

Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy
PubMed 26618550
DOI 10.1038/bmt.2015.286
Knihovny.cz E-zdroje

In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.

000      
00000naa a2200000 a 4500
001      
bmc17000834
003      
CZ-PrNML
005      
20170112123655.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bmt.2015.286 $2 doi
024    7_
$a 10.1038/bmt.2015.286 $2 doi
035    __
$a (PubMed)26618550
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Robinson, S P $u Department of Haematology, University Hospital Bristol NHS Foundation Trust, Bristol, UK.
245    10
$a Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party / $c SP. Robinson, A. Boumendil, H. Finel, D. Blaise, X. Poiré, E. Nicolas-Virelizier, R. Or, R. Malladi, A. Corby, L. Fornecker, D. Caballero, D. Pohlreich, A. Nagler, C. Thieblemont, J. Finke, E. Bachy, L. Vincent, W. Schroyens, H. Schouten, P. Dreger,
520    9_
$a In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a autologní štěp $7 D064592
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x mortalita $x terapie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a recidiva $7 D012008
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    12
$a transplantace kmenových buněk $7 D033581
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Boumendil, A $u Lymphoma Working Party, EBMT, Paris, France.
700    1_
$a Finel, H $u Lymphoma Working Party, EBMT, Paris, France.
700    1_
$a Blaise, D $u Program de Transplantation and Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France.
700    1_
$a Poiré, X $u Department of Haematology, Cliniques Universitaires St. Luc, Brussels, Belgium.
700    1_
$a Nicolas-Virelizier, E $u Department of Haematology, Centre Leon Berard, Lyon, France.
700    1_
$a Or, R $u Department of BMT, Hadassah University Hospital, Jerusalem, Israël.
700    1_
$a Malladi, R $u Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
700    1_
$a Corby, A $u Services des Maladies du Sang, CHU, Angers, France.
700    1_
$a Fornecker, L $u Department of Haematology, Nouvel Hopital Civil, Strasbourg, France.
700    1_
$a Caballero, D $u Servicio de Haematogica, Hospital Clínico, Salamanca, Spain.
700    1_
$a Pohlreich, D $u Department of Medicine, Charles University Hospital, Prague, Czech Republic.
700    1_
$a Nagler, A $u Department of Haematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Thieblemont, C $u APHP Hemato-Oncology Department, Saint-Louis Hospital, Paris, France.
700    1_
$a Finke, J $u Department of Medicine, University of Freiburg, Germany.
700    1_
$a Bachy, E $u Department of Haematology, Hospices Civils de Lyon, Pierre-Benite, France.
700    1_
$a Vincent, L $u Department d'Hematologie Clinique, CHU Lapeyronie, Montpellier, France.
700    1_
$a Schroyens, W $u Department of Haematology, Antwerp University Hospital (UZA), Antwerp Edegem, Belgium.
700    1_
$a Schouten, H $u Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.
700    1_
$a Dreger, P $u Medizinische Klinik, University Of Heidelberg, Heidelberg, Germany.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 51, č. 3 (2016), s. 365-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26618550 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170112123755 $b ABA008
999    __
$a ok $b bmc $g 1179974 $s 961401
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 51 $c 3 $d 365-71 $e 20151130 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace